Capstone Investment Advisors
CTIC

Capstone Investment Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Capstone Investment Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,445
Closed -$149K – 2191
2021
Q3 		$149K Buy
+50,445
New +$137K ﹤0.01% 1737
2021
Q1 		– Sell
-27,770
Closed -$89K – 2040
2020
Q4 		$89K Buy
+27,770
New +$92.4K ﹤0.01% 1572

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Capstone Investment Advisors's CTIC Position: Q4 2021 in Review

Capstone Investment Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2021, closing a stake of 50,445 shares — an estimated $149K sold.

Capstone Investment Advisors first reported a position in CTIC in Q4 2020 and held it in 2 quarters. The position peaked at $149K in Q3 2021. 63 funds tracked by Wall St. Rank hold CTIC as of Q4 2021.

  • Capstone Investment Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 50,445 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2021, an estimated $149K.
  • Capstone Investment Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $149K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.